Wijziging van de Wet geneesmiddelenprijzen in verband met een aanpassing van de referentielanden

This amendment proposes to update the Medicines Prices Act by changing the set of reference countries used to determine the pricing of pharmaceuticals. This ensures that the benchmark for drug pricing remains current and aligned with the Dutch government's pricing policy. The change primarily affects pharmaceutical companies and the healthcare system by altering how the maximum reimbursement prices for medicines are calculated in the Netherlands.